|
186 Products |
| 186 Products |
|
1696 Diseases |  |
95004 News |  |
| «12...173174175176177178179180181182183...10651066» |
- Empliciti (elotuzumab) / AbbVie, BMS, Ninlaro (ixazomib) / Takeda
Real-world treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A retrospective chart study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6018;
This global chart review across the US, Canada, and Western Europe highlights the consistent lack of a standard of care for the management of MM among patients who are refractory to the three main classes of therapies. >P, pomalidomide; d, dexamethasone; K, carfilzomib; Cy, cyclophosphamide; R, lenalidomide; N, ixazomib; E, elotuzumab.
- Tagrisso (osimertinib) / AstraZeneca, Reqorsa (quaratusugene ozeplasmid) / Genprex
ACCLAIM-1 dose escalation: Determination of quaratusugene ozeplasmid and osimertinib recommended phase 2 dose (RP2D). () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4783;
P1/2
Quaratusugene ozeplasmid was generally well tolerated, and was associated with a post-infusion syndrome of fever and chills managed with steroids, acetaminophen and diphenhydramine. Based on these data, the RP2D of quaratusugene ozeplasmid in combination with osimertinib in patients with NSCLC progressing after osimertinib treatment is expected to be 0.12 mg/kg.
- dexamethasone sodium phosphate (AVM0703) / AVM Biotechnology
Immunomodulatory AVM0703 lacks the association between anti-cancer activity and immune-mediated side-effects of the checkpoint Inhibitors. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4623;
1) Tocut, Autoimmun Rev 2018. 2) Sakowska, Front Immunol 2022.
- dexamethasone sodium phosphate (AVM0703) / AVM Biotechnology, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Immunomodulatory AVM0703 enhances R-CHOP anti-lymphoma effect with reduced toxicity: Immune-resistant, aggressive A20 lymphoma model. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4621;
1) Poeschel Lancet 2019. 2) Spurgeon J Natl Canc Inst 2016.
- Legalon (silibinin) / Viatris
Safety and efficacy of silibinin in patients with brain metastases after stereotactc radiosurgery: SUSTAIN trial. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4518;
Toxicity proved manageable, consistent with the literature and limited to gastrointestinal effects. A larger sample and longer follow-up is needed to confirm our hypothesis.
- docetaxel / Generic mfg.
Bioequivalence study of BH009 and Winthrop (docetaxel) injection (an authorized generic drug of Taxotere) in patients with advanced solid tumor: An open-label, randomized, single-dose, two-way crossover evaluation. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4237;
P3
BH009 is the first polysorbate 80-free formulation of docetaxel injection which is bioequivalent to Taxotere and may provide a safer alternative to Taxotere. Clinical trial information: NCT04889599.
- Treatments and outcomes of patients with localized extranodal NK/T-cell lymphoma (ENKL) diagnosed between 2014 and 2021: A cooperative study in Japan. (On Demand | Hall A; Poster Bd # 116) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3969;
RT-DeVIC was more frequently used for first-line treatment of localized ENKL, and its efficacy has been maintained, with 87% 2-yr OS in recent clinical practice in Japan, providing further evidence of RT-DeVIC as a preferred first-line regimen for localized ENKL. No obvious improvement in OS and a reduction in G3 mucositis were observed, suggesting that more efficacious and less toxic regimens need to be introduced.
- Carvykti (ciltacabtagene autoleucel) / J&J
First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. (Live Stream | Hall D1) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3911;
P3
Research Funding Pharmaceutical/Biotech Company Janssen Research & Development, LLC, Legend Biotech USA Inc Background: CARTITUDE-4 is a global, phase 3, randomized, controlled trial (NCT04181827) of ciltacabtagene autoleucel (cilta-cel), a dual-binding, BCMA-targeting CAR-T cell therapy, vs standard of care (SOC; pomalidomide, bortezomib, and dexamethasone [PVd] or daratumumab, pomalidomide, and dexamethasone [DPd]) in lenalidomide (len)-refractory patients (pts). A single cilta-cel infusion significantly improved PFS vs SOC in len-refractory pts with 1
- Comparing the time toxicity of cancer treatments in the CCTG LY.12 trial. (On Demand | Hall A; Poster Bd # 503) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3729;
P3
These measures can add clinical insight into patient burdens. In LY.12, despite broadly comparable short- and long-term oncologic outcomes, the GDP arm experienced less time toxicity.
- dexamethasone / Generic mfg.
A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study. (On Demand | Hall A; Poster Bd # 495) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3721;
Clinical trial information: CTRI/2022/03/040906. >
- dexamethasone / Generic mfg.
Phase 3 RCT of dexamethasone versus placebo for chemotherapy induced fatigue in patients with advanced solid malignancies. (On Demand | Hall A; Poster Bd # 480) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3706;
Clinical trial information: CTRI/2018/08/015222. >*T-Test.
- dexamethasone / Generic mfg.
Dexamethasone and exercise for cancer-related fatigue: A phase III randomized controlled trial. (On Demand | Hall A; Poster Bd # 466) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3692;
The intervention significantly improved QoL fatigue symptom score and reduced physical fatigue on QoL, along with improving sleep quality. Clinical trial information: CTRI/2022/09/045678.
- giredestrant (GDC-9545) / Roche
evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2 (On Demand | Hall A; Poster Bd # 336a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3311;
P3
Clinical trial information: CTRI/2022/09/045678. Fulvestrant
- Darzalex Faspro (daratumumab/hyaluronidase) / J&J
Incidence of infusion related reactions of daratumumab-hyaluronidase-fihj: Pre-post intervention study of premedication omission. (On Demand | Hall A; Poster Bd # 66) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2673;
IRRs to Dara-SQ occur early, are rare, and mild in course. Omitting premedication after a minimum of four Dara-SQ doses is safe and carries substantial time savings for patients and infusion centers.
- A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000. (On Demand | Hall A; Poster Bd # 360b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2577;
P2
In the Checkmate-204 trial of ipilimumab with nivolumab in MBM, the 6-month progression free survival (PFS) rate was 19% with a median PFS of only 1.2 months in symptomatic participants (those with neurological symptoms including steroids up to 4 mg/day of dexamethasone, n=18)...The single-arm phase 2 TRICOTEL study explored the triplet regimen of vemurafenib + cobimetinib + atezolizumab in MBM; in the symptomatic brain met cohort, 6-month PFS was 57% (n=24)...Funding: NIH/NCI grants U10CA180888, U10CA180819, U10CA180820 U10CA180868; and in part by Pfizer, Inc. Clinical trial information: NCT04511013.
- Opdivo (nivolumab) / Ono Pharma, BMS
Safety and preliminary efficacy of intrathecal (IT) and intravenous (IV) nivolumab (N) for patients (pts) with leptomeningeal disease (LMD). (On Demand | Hall A; Poster Bd # 317) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2531;
P1
Overall results also demonstrate the feasibility of prospective clinical trials in pts with LMD. Final presentation will also include immunological analysis of longitudinally collected CSF samples collected in the trial.
- Orencia (abatacept) / BMS
Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): Phase 3, investigator-initiated, randomized, placebo-controlled study to evaluate the efficacy and safety of abatacept compared to placebo in hospitalized patients with immune checkpoint inhibitor associated myocarditis. (On Demand | Hall A; Poster Bd # 513b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2444;
P3
Target enrollment is 390 patients. Clinical trial information: NCT05335928.
- Yervoy (ipilimumab) / Ono Pharma, BMS
Immune-related adrenal insufficiency: A single center retrospective analysis. (On Demand | Hall A; Poster Bd # 501) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2424;
Detection of irAI before clinical presentation let us prevent severe consequences including life threating. We consider that routine cortisol assessment during immunotherapy should be implemented in clinical practice.
- relacorilant (CORT125134) / Corcept Therap
Phase I trial of enzalutamide (Enz) plus the glucocorticoid receptor antagonist relacorilant (Rela) for patients with metastatic castration resistant prostate cancer. (On Demand | Hall A; Poster Bd # 156) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1630;
P1
The majority of pts were discontinued from trial due to progressive disease or hospice. Further analyses of secondary & correlative endpoints such as translational/endocrine biomarkers, GR target gene expression and circulating tumor cells are ongoing.
- Identification of genes encoding targets associated with adverse events in multiple myeloma. (On Demand | Hall A; Poster Bd # 150) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1506;
When considering alternative agents in MM, our study offers insights for predicting treatment responses such as PSMB8 which could potentially cause an off target effect of K on cardiomyocyte 20S beyond MM cells. Our plan is to integrate this novel computational biology approach with translational medicine to further investigate our observation.
- Blenrep (belantamab mafodotin) / GSK
A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9. (On Demand | E450; Poster Bd # 10) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1441;
P1
Clinical trial information: NCT04091126. >
- mezigdomide (BMS-986348) / BMS
A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2. (On Demand | Hall A; Poster Bd # 58b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1427;
P3
C2; and 20 mg oral/IV DEX (10 mg optional in certain pt groups) on D1, 2, 8, 9, 15, 16, 22, and 23...Enrollment began in October 2022 and is ongoing. Clinical trial information: NCT05552976.
- Darzalex (daratumumab) / J&J, iberdomide (CC-220) / BMS
EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). (On Demand | Hall A; Poster Bd # 58a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1426;
P3
Enrollment began in June 2022 and is currently ongoing. Clinical trial information: NCT04975997.
- ANV419 / Anaveon
OMNIA-2: Phase I/II study of ANV419, an IL-2R-?? targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma. (On Demand | Hall A; Poster Bd # 57b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1425;
P1
The OMNIA-2 study (ANV419-102; NCT 05641324) will evaluate safety and preliminary efficacy of ANV419 as monotherapy and in combination with daratumumab (dara), or lenalidomide with low dose dexamethasone (lena/dex), in patients with relapsed or refractory multiple myeloma...OMNIA-2 is being conducted in Denmark, France, Germany, Spain, Switzerland, UK and enrolment began in January 2023 and preliminary data are expected in Q1 2024. Clinical trial information: NCT05641324.
- Tecvayli (teclistamab) / Genmab, J&J
MajesTEC-9: A randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. (On Demand | Hall A; Poster Bd # 57a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1424;
P3
The study opened in January 2023 and enrollment is ongoing. Clinical trial information: NCT05572515.
- elranatamab (PF-06863135) / Pfizer, Darzalex (daratumumab) / J&J
MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM). (On Demand | Hall A; Poster Bd # 56a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1422;
P2, P3
As of February 2023, the study is open and enrolling at 9 sites in 5 countries. Clinical trial information: NCT05623020.
- Darzalex (daratumumab) / J&J
A phase 2 evaluation of daratumumab-based induction therapy in patients with multiple myeloma with severe renal insufficiency. (On Demand | Hall A; Poster Bd # 49) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1414;
P2
Clinical trial information: NCT05623020. We used a Simon
- Ninlaro (ixazomib) / Takeda, Darzalex Faspro (daratumumab/hyaluronidase) / J&J
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du My (On Demand | Hall A; Poster Bd # 46) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1411;
P2
We used a Simon Ixa-Dara na
- Blenrep (belantamab mafodotin) / GSK
Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study. (On Demand | Hall A; Poster Bd # 42) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1408;
P1/2
The combination induced rapid and deep responses, with all pts achieving ?PR and first response observed at a median of 1 month. Clinical trial information: NCT04808037.
- tasquinimod (ABR-215050) / Active Biotech, Ipsen
Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM). (On Demand | Hall A; Poster Bd # 34) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1400;
P1
Tasq has anti-myeloma activity in combination with IRd, as evidenced by a partial response in a patient previously refractory to Imid/PI combination therapy. Enrollment continues to tasq with IRd at dose level 2.
- Darzalex (daratumumab) / J&J
Adjusted indirect treatment comparison of progression-free survival (PFS) associated with DRd and VRd based on MAIA and SWOG S0777 individual patient-level data. (On Demand | Hall A; Poster Bd # 29) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1395;
In this adjusted indirect treatment comparison based on IPD from the MAIA and S0777 trials, PFS was significantly longer for DRd relative to VRd. In the absence of a head-to-head trial comparing DRd and VRd, the present study may help to inform treatment selection in TIE patients with NDMM.
- Orencia (abatacept) / BMS, Ninlaro (ixazomib) / Takeda
Phase 2 study of abatacept, ixazomib, and dexamethasone in patients with relapsed/refractory multiple myeloma. (On Demand | Hall A; Poster Bd # 22) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1388;
P2
Patients with response stayed on treatment for almost 1 year on average with limited AEs. Most patients on trial gained benefit with a clinical benefit rate (CR+PR+SD) of 86.66%.
- Sarclisa (isatuximab-irfc) / Sanofi
Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+ status: Updated results from the phase 3 IKEMA study. (On Demand | Hall A; Poster Bd # 21) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1387;
P3
Our results at long-term follow-up of pts with 1q21+ status (with or without HRCA) in the IKEMA study continue to show greater PFS benefit and deeper responses with Isa-Kd than Kd, consistent with the overall population and earlier 1q21+ subgroup interim analyses. Thus, they support Isa-Kd as an effective treatment option also for difficult-to-treat, 1q21+ pts with relapsed MM.
- Blenrep (belantamab mafodotin) / GSK
A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM?3. (Live Stream | Hall D2) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1376;
P2, P3
However, median PFS was longer for belamaf monotherapy and belamaf induced deeper, more durable responses than Pd. No new safety signals were observed.
- dexamethasone / Generic mfg., carfilzomib / Generic mfg., pomalidomide / Generic mfg.
Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma patients (pts): A phase 2 study with a safety run-in. (Live Stream | Hall D2) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1368;
P2
MRD negativity (10-5) was attained in 80% of pts. Despite the encouraging results in this cohort of high-risk patients, PFS and OS among double-hit pts remains poor, warranting newer strategies aimed at remission sustenance.
- Empliciti (elotuzumab) / AbbVie, BMS
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study. (Live Stream | Hall D2) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1367;
P3
E-KRd pts had slightly more TEAEs. Events were mainly hematotoxicity.
- Keytruda (pembrolizumab) / Merck (MSD), Hyleukin-7 (efineptakin alfa) / Genexine, NeoImmuneTech
Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma. (Available On Demand; Poster Bd # 439b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1118;
P2
Two of the planned 30 patients had been enrolled by submission on 2/14/2023. Clinical trial information: NCT05465954.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Prospective phase I study of checkpoint blockade for the treatment of patients with newly diagnosed high-grade glioma prior to radiochemotherapy: Results of nivolumab plus ipilimumab treatment arm. (Available On Demand; Poster Bd # 414) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1090;
P1
To our knowledge, this is the first study in which checkpoint blockade therapy was administered for newly diagnosed glioblastoma prior to standard radiotherapy. Despite the short mPFS, mOS was suggestive of a potential long-term benefit from early CPI exposure, and three patients deferred chemoradiation greater than seven months.
- AV-GBM-1 / AiVita Biomedical
Final results of phase 2 trial of personal dendritic cell (DC) vaccines loaded with autologous tumor antigens (ATA) in newly diagnosed glioblastoma (GBM). (Available On Demand; Poster Bd # 404) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1080;
P2
PFS was encouraging, but did not translate into improved OS, perhaps because DC-ATA was limited to 8 injections. Clinical trial information: NCT03400917.
- Zynyz (retifanlimab-dlwr) / Incyte, Avastin (bevacizumab) / Roche, ragifilimab (INCAGN1876) / Incyte
PD1 inhibition and GITR agonism in combination with fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma: A phase 2, multi-arm study. (Available On Demand) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1051;
P2
However, among patients receiving neoadjuvant immunotherapy prior to surgical resection, the addition of neoadjuvant FSRT was associated with a significant survival advantage as well as increased inflammatory and cellular immune responses. Neoadjuvant FSRT + ICB warrants further evaluation in rGBM.
- | dexamethasone / Generic mfg.
Journal, Heterogeneity, Machine learning: Causal Bayesian machine learning to assess treatment effect heterogeneity by dexamethasone dose for patients with COVID-19 and severe hypoxemia. (Pubmed Central) - Apr 26, 2023
Neoadjuvant FSRT + ICB warrants further evaluation in rGBM. We found that 12
- | methylphenidate tablet / Generic mfg., hydrocortisone / Generic mfg., disulfiram / Generic mfg.
Retrospective data, Journal: Risk of non-hypoglycemic agents for hypoglycemia-related hospitalization in patients with type 2 diabetes: a large-scale medical receipt database analysis. (Pubmed Central) - Apr 26, 2023
This large retrospective analysis revealed that the risk of HRH from some non-hypoglycemic agents in patients with T2D may be increased. The results of this study are expected to support treatment planning by physicians and healthcare professionals involved in diabetes care.
- | budesonide / Generic mfg.
Journal: Targeted-release budesonide in recurrent IgA nephropathy after kidney transplantation. (Pubmed Central) - Apr 26, 2023
The results of this study are expected to support treatment planning by physicians and healthcare professionals involved in diabetes care. No abstract available
- || dexamethasone / Generic mfg.
Review, Journal, Immunomodulating: Immunomodulatory Agents for Coronavirus Disease-2019 Pneumonia. (Pubmed Central) - Apr 26, 2023
Corticosteroids, specifically dexamethasone, have been shown to reduce mortality in hospitalized patients who require supplemental oxygen...However, patients who have severe pulmonary end-organ damage requiring mechanical ventilation or extracorporeal membrane oxygenation appear not to benefit from immunomodulatory therapies. This highlights the importance of appropriate timing to initiate immunomodulatory therapies in the management of severe COVID-19 disease.
- | remifentanil / Generic mfg., dexamethasone injection / Generic mfg., ropivacaine / Generic mfg.
Journal: The Role of Ultrasound-Guided Multipoint Fascial Plane Block in ElderlyPatients Undergoing Combined Thoracoscopic-Laparoscopic Esophagectomy: A Prospective Randomized Study. (Pubmed Central) - Apr 26, 2023
This highlights the importance of appropriate timing to initiate immunomodulatory therapies in the management of severe COVID-19 disease. This study showed that applying the multipoint fascia pane block technique in TLE for elderly patients could significantly reduce postoperative pain, decrease the dosages of drugs used in general anesthesia, improve the quality of the awakening, and have no obvious adverse reactions.
- | triamcinolone acetonide / Generic mfg.
Journal: Development of triamcinolone acetonide-hyaluronic acid conjugates with selective targeting and less osteoporosis effect for rheumatoid arthritis treatments. (Pubmed Central) - Apr 26, 2023
Furthermore, in a collagen-antibody-induced arthritis animal study, HA-TA conjugates enhanced the initiative targeting ability to inflame tissue and reduce the histopathological arthritic changes (score?=?0). Additionally, the level of bone formation marker P1NP in HA-TA-treated ovariectomized mice (303.6?
- ||||| Barhemsys (intravenous amisulpride) / Eagle Pharma
Trial initiation date: Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients (clinicaltrials.gov) - Apr 26, 2023
P2/3, N=410, Not yet recruiting, Sponsor: Acacia Pharma Ltd
Additionally, the level of bone formation marker P1NP in HA-TA-treated ovariectomized mice (303.6? Initiation date: Dec 2022 --> May 2023
- | Ninlaro (ixazomib) / Takeda
Trial completion date: Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia (clinicaltrials.gov) - Apr 26, 2023
P2, N=17, Active, not recruiting, Sponsor: Mayo Clinic
Initiation date: Dec 2022 --> May 2023 Trial completion date: Dec 2022 --> Jun 2023
- |||||||| DuoResp Spiromax (budesonide/formoterol) / Teva
New P3 trial: EXACT@home: Expertise Asthma COPD Program With Digital Support (clinicaltrials.gov) - Apr 26, 2023
P3, N=138, Recruiting, Sponsor: Franciscus Gasthuis
- ||| Riarify (beclometasone/formoterol/glycopyrrolate) / Chiesi
New P1 trial: A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV) (clinicaltrials.gov) - Apr 26, 2023
P1, N=95, Recruiting, Sponsor: Chiesi Farmaceutici S.p.A.